← ANALYST RATINGS · TIPRANKS
Orchestra BioMed Holdings (OBIO): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $13.00, the highest $15.00, the lowest $11.00. The average is +138.5% from the last price of $5.45.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.00 → $5.50−8.3% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.00 → $5.50−8.3% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.00 → $5.50−8.3% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.00 → $5.50−8.3% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $10.00 → $12.00+20.0% | Buy | +120.2% | Reiterated | 15.10.26on TipRanks 07:55 | +1.5%next day −3.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $6.00−7.7% | Hold | +10.1% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.50 → $6.00−7.7% | Hold | +10.1% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $6.00−7.7% | Hold | +10.1% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 → $5.50−8.3% | Hold | +0.9% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.50 → $6.00−7.7% | Hold | +10.1% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $5.50−15.4% | Hold | +0.9% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $10.00 | Buy | +83.5% | Reiterated | 02.10.26on TipRanks 12:15 | −7.0%next day +0.7% · 5 days −1.2% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $11.00 | Buy | +101.8% | Reiterated | 02.10.26on TipRanks 08:50 | −7.0%next day +0.7% · 5 days −1.2% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.00 → $6.50+8.3% | Hold | +19.3% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.00 → $6.50+8.3% | Hold | +19.3% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.00 → $6.50+8.3% | Hold | +19.3% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 | Hold | +19.3% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.50 → $6.00−7.7% | Hold | +10.1% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $6.00−7.7% | Hold | +10.1% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 | Hold | +10.1% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.50 | Hold | +19.3% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $6.00−7.7% | Hold | +10.1% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $15.00 | Buy | +175.2% | Reiterated | 25.09.26on TipRanks 07:30 | −0.5%next day −0.3% · 5 days +0.2% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $10.00 → $11.00+10.0% | Buy | +101.8% | Initiated | 15.09.26on TipRanks 08:25 | +2.8%next day −0.1% · 5 days +0.6% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $10.00 | Buy | +83.5% | Upgrade | 10.09.26on TipRanks 05:50 | +7.2%next day +4.5% · 5 days −1.1% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $10.00 | Buy | +83.5% | Reiterated | 13.08.26on TipRanks Aug 12 13:15 | +0.2%next day 0.0% · 5 days +26.0% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $9.00 → $10.00+11.1% | Buy | +83.5% | Reiterated | 11.08.26on TipRanks 06:55 | −1.0%next day +0.2% · 5 days +29.0% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $12.00 → $13.00+8.3% | Buy | +138.5% | Assigned | 13.05.26on TipRanks 04:45 | −0.6%next day +0.4% · 5 days −1.8% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $20.00 | Buy | +267.0% | Reiterated | 12.03.26on TipRanks 14:11 | −3.3%next day −3.5% · 5 days +6.9% | ↗ |
| Unknown Analyst | Jefferies | $10.00 | Buy | +83.5% | Reiterated | 15.01.26on TipRanks 10:15 | −6.8%next day +1.3% · 5 days −2.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Orchestra BioMed Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $11.20 at a price of $6.22 (+80.1%); now: $11.60 at $5.45 (+112.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 3 | 0 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.40 (from $-0.45 to $-0.37). Last quarter: $-0.38.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Orchestra BioMed Holdings
- CEO: David Hochman
- Employees: 86
- 150 Union Square Drive, New Hope, PA, 18938, US
- orchestrabiomed.com
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 58 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗